| William Rossmiller, PT, DPT | |
|
1306 Highway 57 Ste B, Parkersburg, IA 50665-1075 | |
| (319) 346-9783 | |
| (319) 346-9785 |
| Full Name | William Rossmiller |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine & Rehabilitation |
| Location | 1306 Highway 57 Ste B, Parkersburg, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255057949 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 114002 (Iowa) | Primary |
| Entity Name | Taylor Physical Therapy Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1861591745 PECOS PAC ID: 1951405174 Enrollment ID: O20141029002365 |
News Archive
Researchers have identified an approach to remove race from equations used to estimate a person's kidney function. These equations have been criticized for potentially perpetuating racial health disparities. The findings, reported September 23 in the New England Journal of Medicine, are expected to inform National Kidney Foundation–American Society of Nephrology Task Force guidelines on evaluating kidney function.
Dr. Glen Weiss of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare this week announced two significant advances in treating lung cancer at an international cancer research conference.
The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs.
Phico Therapeutics Ltd, a Cambridge-based company that has developed a unique anti-bacterial technology to treat the hospital superbug, MRSA, has raised £550,000 with the help of Oxfordshire Investment Opportunity Network, Europe's leading technology business angel network.
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William Rossmiller, PT, DPT 1306 Highway 57 Ste B, Parkersburg, IA 50665-1075 Ph: (319) 346-9783 | William Rossmiller, PT, DPT 1306 Highway 57 Ste B, Parkersburg, IA 50665-1075 Ph: (319) 346-9783 |
News Archive
Researchers have identified an approach to remove race from equations used to estimate a person's kidney function. These equations have been criticized for potentially perpetuating racial health disparities. The findings, reported September 23 in the New England Journal of Medicine, are expected to inform National Kidney Foundation–American Society of Nephrology Task Force guidelines on evaluating kidney function.
Dr. Glen Weiss of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare this week announced two significant advances in treating lung cancer at an international cancer research conference.
The need to distinguish between normal cells and tumor cells is a feature that has been long sought for most types of cancer drugs.
Phico Therapeutics Ltd, a Cambridge-based company that has developed a unique anti-bacterial technology to treat the hospital superbug, MRSA, has raised £550,000 with the help of Oxfordshire Investment Opportunity Network, Europe's leading technology business angel network.
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug.
› Verified 9 days ago